vs
Side-by-side financial comparison of NUSATRIP Inc (NUTR) and RELMADA THERAPEUTICS, INC. (RLMD). Click either name above to swap in a different company.
RELMADA THERAPEUTICS, INC. is the larger business by last-quarter revenue ($1.3M vs $768.7K, roughly 1.6× NUSATRIP Inc).
NUSATRIP Inc is a travel technology company that operates a full-service online travel booking platform primarily catering to Southeast Asian markets. It provides flight ticketing, hotel accommodation reservations, customized holiday packages, and local experience bookings for both leisure travelers and small business travel clients.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies for central nervous system disorders. Its lead product candidate targets treatment-resistant depression, with ongoing clinical trials to address unmet medical needs in its primary markets of North America and Europe.
NUTR vs RLMD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $768.7K | $1.3M |
| Net Profit | $-963.7K | — |
| Gross Margin | 100.0% | — |
| Operating Margin | -162.3% | -2130.6% |
| Net Margin | -125.4% | — |
| Revenue YoY | — | 13.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $-0.17 | $-0.84 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $768.7K | — | ||
| Q2 25 | $993.0K | — | ||
| Q4 23 | — | $1.3M | ||
| Q3 23 | — | $1.3M | ||
| Q2 23 | — | $1.4M | ||
| Q1 23 | — | $1.2M | ||
| Q4 22 | — | $1.1M | ||
| Q3 22 | — | $827.6K |
| Q3 25 | $-963.7K | — | ||
| Q2 25 | $920.3K | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | $-22.0M | ||
| Q2 23 | — | $-25.3M | ||
| Q1 23 | — | $-26.3M | ||
| Q4 22 | — | $-37.9M | ||
| Q3 22 | — | $-39.4M |
| Q3 25 | 100.0% | — | ||
| Q2 25 | 100.0% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | -162.3% | — | ||
| Q2 25 | 41.2% | — | ||
| Q4 23 | — | -2130.6% | ||
| Q3 23 | — | -1717.3% | ||
| Q2 23 | — | -1908.9% | ||
| Q1 23 | — | -2331.3% | ||
| Q4 22 | — | -3472.5% | ||
| Q3 22 | — | -4680.6% |
| Q3 25 | -125.4% | — | ||
| Q2 25 | 92.7% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | -1665.0% | ||
| Q2 23 | — | -1855.9% | ||
| Q1 23 | — | -2179.6% | ||
| Q4 22 | — | -3404.5% | ||
| Q3 22 | — | -4762.9% |
| Q3 25 | $-0.17 | — | ||
| Q2 25 | $0.25 | — | ||
| Q4 23 | — | $-0.84 | ||
| Q3 23 | — | $-0.73 | ||
| Q2 23 | — | $-0.84 | ||
| Q1 23 | — | $-0.87 | ||
| Q4 22 | — | — | ||
| Q3 22 | — | $-1.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.1M | $96.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $12.5M | $85.4M |
| Total Assets | $27.0M | $97.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $5.1M | — | ||
| Q2 25 | $6.9M | — | ||
| Q4 23 | — | $96.3M | ||
| Q3 23 | — | $106.3M | ||
| Q2 23 | — | $118.5M | ||
| Q1 23 | — | $132.4M | ||
| Q4 22 | — | $148.3M | ||
| Q3 22 | — | $141.6M |
| Q3 25 | $12.5M | — | ||
| Q2 25 | $-1.9M | — | ||
| Q4 23 | — | $85.4M | ||
| Q3 23 | — | $100.7M | ||
| Q2 23 | — | $111.3M | ||
| Q1 23 | — | $125.5M | ||
| Q4 22 | — | $140.4M | ||
| Q3 22 | — | $166.3M |
| Q3 25 | $27.0M | — | ||
| Q2 25 | $19.3M | — | ||
| Q4 23 | — | $97.6M | ||
| Q3 23 | — | $109.1M | ||
| Q2 23 | — | $122.0M | ||
| Q1 23 | — | $135.6M | ||
| Q4 22 | — | $152.9M | ||
| Q3 22 | — | $187.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-17.0M | $-10.2M |
| Free Cash FlowOCF − Capex | $-17.0M | — |
| FCF MarginFCF / Revenue | -2207.9% | — |
| Capex IntensityCapex / Revenue | 0.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-17.0M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q4 23 | — | $-10.2M | ||
| Q3 23 | — | $-11.6M | ||
| Q2 23 | — | $-13.3M | ||
| Q1 23 | — | $-16.5M | ||
| Q4 22 | — | $-35.9M | ||
| Q3 22 | — | $-26.9M |
| Q3 25 | $-17.0M | — | ||
| Q2 25 | $-1.5M | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | -2207.9% | — | ||
| Q2 25 | -152.2% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | 0.6% | — | ||
| Q2 25 | 0.5% | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | -1.64× | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | — | — | ||
| Q4 22 | — | — | ||
| Q3 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
